Limits...
Combined treatment with an oncolytic adenovirus and antitumor activity of vincristine against retinoblastoma cells.

Song X, Wang H, Jia R, Cun B, Zhao X, Zhou Y, Xu X, Qian G, Ge S, Fan X - Int J Mol Sci (2012)

Bottom Line: The combination therapy exerted a synergistic antitumor effect via a type of G(2)/M and S phase arrest rather than the induction of apoptosis.The combination of VCR and SG600 further reduced Akt phosphorylation compared with cells treated with VCR alone, suggesting that SG600 could overcome chemoresistance, perhaps by down-regulating Akt in RB cells.An increase in the expression of p-p53 and decrease in p-Rb expression in HXO-RB(44) after co-treatment might be associated with cell cycle block.

View Article: PubMed Central - PubMed

Affiliation: Department of Ophthalmology, Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China; E-Mails: songxin0521@hotmail.com (X.S.); jrb6@sina.com (R.J.); catherine1_2_3@163.com (B.C.); zxp0856@sina.com (X.Z.); zhouyixiong21@gmail.com (Y.Z.); xuxu0139@hotmail.com (X.X.).

ABSTRACT
Treatment trends of retinoblastoma (RB) have gradually evolved from eye enucleation and external radiation to local treatment. Combined treatment with an oncolytic virus and chemotherapy is currently a new method in RB treatment. To investigate the therapeutic effect of oncolytic adenovirus SG600 in combination with vincristine (VCR) on retinoblastoma in vitro, the cell viability, cell cycle effects and apoptotic activity of HXO-RB(44) cells treated with SG600, VCR or SG600 plus VCR were measured using a cell counting kit-8-based procedure and flow cytometry. Western blot analysis for Akt, p-Akt, p-p53 and p-Rb protein was performed to investigate the underlying mechanisms of combined therapy. The combination therapy exerted a synergistic antitumor effect via a type of G(2)/M and S phase arrest rather than the induction of apoptosis. The combination of VCR and SG600 further reduced Akt phosphorylation compared with cells treated with VCR alone, suggesting that SG600 could overcome chemoresistance, perhaps by down-regulating Akt in RB cells. An increase in the expression of p-p53 and decrease in p-Rb expression in HXO-RB(44) after co-treatment might be associated with cell cycle block. Western blot examination revealed that VCR might enhance SG600 replication. These results suggest that viro-chemo combination therapy is a feasible and potentially promising approach for the treatment of retinoblastoma.

No MeSH data available.


Related in: MedlinePlus

Detection of apoptosis in HXO-RB44 cells. Apoptosis was measured by flow cytometry analysis 48 h after treatment with VCR (5 nM), SG600, and VCR plus SG600. Results are representative of three independent experiments. NC (negative control): treatment with PBS.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC3472711&req=5

f4-ijms-13-10736: Detection of apoptosis in HXO-RB44 cells. Apoptosis was measured by flow cytometry analysis 48 h after treatment with VCR (5 nM), SG600, and VCR plus SG600. Results are representative of three independent experiments. NC (negative control): treatment with PBS.

Mentions: To investigate the underlying mechanism of combination treatment, we analyzed apoptosis of HXO-RB44 cells when exposed to the various therapies. Forty-eight hours after treatment, apoptosis was assessed using flow cytometry and an Annexin V-FITC apoptosis kit. As seen in Figure 4, monotherapy with 5 nM VCR (4.32%) or SG600 (3.44%–3.56%) as well as combination treatment (4.43%–4.67%) did not induce a high level of apoptosis compared with the PBS control (3.34%).


Combined treatment with an oncolytic adenovirus and antitumor activity of vincristine against retinoblastoma cells.

Song X, Wang H, Jia R, Cun B, Zhao X, Zhou Y, Xu X, Qian G, Ge S, Fan X - Int J Mol Sci (2012)

Detection of apoptosis in HXO-RB44 cells. Apoptosis was measured by flow cytometry analysis 48 h after treatment with VCR (5 nM), SG600, and VCR plus SG600. Results are representative of three independent experiments. NC (negative control): treatment with PBS.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC3472711&req=5

f4-ijms-13-10736: Detection of apoptosis in HXO-RB44 cells. Apoptosis was measured by flow cytometry analysis 48 h after treatment with VCR (5 nM), SG600, and VCR plus SG600. Results are representative of three independent experiments. NC (negative control): treatment with PBS.
Mentions: To investigate the underlying mechanism of combination treatment, we analyzed apoptosis of HXO-RB44 cells when exposed to the various therapies. Forty-eight hours after treatment, apoptosis was assessed using flow cytometry and an Annexin V-FITC apoptosis kit. As seen in Figure 4, monotherapy with 5 nM VCR (4.32%) or SG600 (3.44%–3.56%) as well as combination treatment (4.43%–4.67%) did not induce a high level of apoptosis compared with the PBS control (3.34%).

Bottom Line: The combination therapy exerted a synergistic antitumor effect via a type of G(2)/M and S phase arrest rather than the induction of apoptosis.The combination of VCR and SG600 further reduced Akt phosphorylation compared with cells treated with VCR alone, suggesting that SG600 could overcome chemoresistance, perhaps by down-regulating Akt in RB cells.An increase in the expression of p-p53 and decrease in p-Rb expression in HXO-RB(44) after co-treatment might be associated with cell cycle block.

View Article: PubMed Central - PubMed

Affiliation: Department of Ophthalmology, Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China; E-Mails: songxin0521@hotmail.com (X.S.); jrb6@sina.com (R.J.); catherine1_2_3@163.com (B.C.); zxp0856@sina.com (X.Z.); zhouyixiong21@gmail.com (Y.Z.); xuxu0139@hotmail.com (X.X.).

ABSTRACT
Treatment trends of retinoblastoma (RB) have gradually evolved from eye enucleation and external radiation to local treatment. Combined treatment with an oncolytic virus and chemotherapy is currently a new method in RB treatment. To investigate the therapeutic effect of oncolytic adenovirus SG600 in combination with vincristine (VCR) on retinoblastoma in vitro, the cell viability, cell cycle effects and apoptotic activity of HXO-RB(44) cells treated with SG600, VCR or SG600 plus VCR were measured using a cell counting kit-8-based procedure and flow cytometry. Western blot analysis for Akt, p-Akt, p-p53 and p-Rb protein was performed to investigate the underlying mechanisms of combined therapy. The combination therapy exerted a synergistic antitumor effect via a type of G(2)/M and S phase arrest rather than the induction of apoptosis. The combination of VCR and SG600 further reduced Akt phosphorylation compared with cells treated with VCR alone, suggesting that SG600 could overcome chemoresistance, perhaps by down-regulating Akt in RB cells. An increase in the expression of p-p53 and decrease in p-Rb expression in HXO-RB(44) after co-treatment might be associated with cell cycle block. Western blot examination revealed that VCR might enhance SG600 replication. These results suggest that viro-chemo combination therapy is a feasible and potentially promising approach for the treatment of retinoblastoma.

No MeSH data available.


Related in: MedlinePlus